期刊文献+

神经氨酸酶抑制剂扎那米韦的药理作用与临床应用 被引量:3

Pharmacologic effects and clinical application of neuraminidase inhibitor zanamivir
原文传递
导出
摘要 扎那米韦是一种神经氨酸酶抑制剂,为WHO推荐的抗流感病毒药物。扎那米韦分子极性强、水溶性大、组织渗透能力差,经口腔吸入或滴鼻给药,可使局部药物浓度高,从而快速有效地抑制病毒的复制和扩散。扎那米韦可用于成人或儿童的甲型或乙型流感的预防和治疗,经口腔吸入或滴鼻给药法可减少用药剂量和不良反应发生率。 Zanamivir, the neuraminidase inhibitor, is recommended by World Health Organization (WHO) for curing influenza infection. Zanamivir has strong molecular polarity, high solubility in water and poor tissue penetration capacity. Oral inhaled or intranasal zanamivir can make high local drug concentrations and inhibit the replication and release of viral particles effectively and fast. Zanamivir is approved for the treatment and prophylaxis of influenza A and B infection in adult and pediatric patients. Oral inhaled or intranasal administration can decrease the drug dosage and the incidence of adverse reactions in patients with influenza infection.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2013年第8期614-618,共5页 Chinese Journal of New Drugs and Clinical Remedies
基金 十二五重大新药创制项目(2011ZX09302-003-01)
关键词 扎那米韦 神经氨酸酶 药理作用 临床应用 安全 zanamivir neuraminidase pharmacologic actions clinical application safety
  • 相关文献

参考文献41

  • 1World health organization. State of the art of vaccine research and development [EB/OL]. (2005-01)[2012-02-17].http://www. who.int/vaecine_research/documents/Dip%20814.pdf.
  • 2NAIR H, BROOKS WA, KATZ M, et ol. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis[J]. Lancet, 2011, 378(9807) : 1917-1930.
  • 3SUGAYA N. Widespread use of neuraminidase inhibitors in Japan[J]. J Infect Chemother, 2011, 17(5): 595-601.
  • 4HOIZER CT, von ITZSTEIN M, JIN B, et al. Inhibition of sialidases from viral, bacterial and mammalian sources by analogs of 2 - deoxy - 2,3 - didehydro - N - acetylneuraminie acid modified at the C-4 position[J]. Glycoconj J, 1993, 10(1): 40- 44.
  • 5PEGG MS, yon ITZSTEIN M. Slow- binding inhibition of sialidase from influenza virus [J]. Biochem Mol Biol Int, 1994, 32(5): 851-858.
  • 6von ITZSTEIN M, WU WY, KOK GB, et al. Rational design of potent sialidase- based inhibitors of influenza virus replication [J]. Nature, 1993, 363(6428) : 418-423.
  • 7刘凤琴.抗甲型H_1N_1流感前沿新药物扎那米韦[J].药物流行病学杂志,2009,18(4):298-299. 被引量:6
  • 8World health organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses [EB/OL].(2010-02)[2012-02-17]. http://www. who.int/csr/resources/publications/swineflu/hlnl use antivirals _20090820/en/.
  • 9黄平,邹丽容,陈秋霞,柯昌文,李晖,方苓.广东地区人禽流感H5N1毒株神经氨酸酶基因的特征与变异[J].中华传染病杂志,2007,25(10):589-592. 被引量:8
  • 10黄平,俞守义,柯昌文.逐步预测和统计学筛选人H5N1毒株神经氨酸酶蛋白B细胞表位[J].科学通报,2008,53(22):2748-2753. 被引量:15

二级参考文献22

共引文献23

同被引文献34

引证文献3

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部